Although biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) have been investigated for use in guiding the discontinuation of antibiotics, their precise role and utility, particularly in cases of severe infection, in immunocompromised patients, and in patients with MDR-GNB, require further validation through robust clinical trials [120,121]. The gene discussed is CRP; the disease is infection.